Search Results - Youngchul Song
- Showing 1 - 18 results of 18
-
1
-
2
-
3
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2 by Brent N. Rexer, Ritwik Ghosh, Archana Narasanna, Mónica V. Estrada, Anindita Chakrabarty, Youngchul Song, Jeffrey A. Engelman, Carlos L. Arteaga
Published 2013Artigo -
4
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins by Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria G. Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga, Jeffrey A. Engelman
Published 2008Artigo -
5
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 by Hiromichi Ebi, Carlotta Costa, Anthony C. Faber, Madhuri Nishtala, Hiroshi Kotani, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino‐Kenudson, Cyril H. Benes, Jeffrey A. Engelman
Published 2013Artigo -
6
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers by Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril H. Benes, Jeffrey Settleman, Kwok‐Kin Wong, Lewis C. Cantley, Jeffrey A. Engelman
Published 2011Artigo -
7
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation by Birgit Schoeberl, Anthony C. Faber, Danan Li, Mei‐Chih Liang, Katherine Crosby, Matthew Onsum, Olga Burenkova, Emily Pace, Zandra E. Walton, Lin Nie, Aaron Fulgham, Youngchul Song, Ulrik B. Nielsen, Jeffrey A. Engelman, Kwok‐Kin Wong
Published 2010Artigo -
8
Combined targeting of HER2 and VEGFR2 for effective treatment of<i>HER2</i>-amplified breast cancer brain metastases by David P. Kodack, Euiheon Chung, Hiroshi Yamashita, João Incio, Annique M. Duyverman, Youngchul Song, Christian T. Farrar, Yuhui Huang, Eleanor I Ager, Walid S. Kamoun, Shom Goel, Matija Snuderl, Alisha Lussiez, Lotte Hiddingh, Sidra Mahmood, Bakhos A. Tannous, April F. Eichler, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
Published 2012Artigo -
9
Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients by Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa B. Schrock, Tianjun Zhou, César Serrano, Grant Eilers, Mei‐Jun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera
Published 2014Artigo -
10
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling by Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Published 2007Artigo -
11
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers by Jeffrey A. Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R. Guimarães, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A. Perera, Youngchul Song, Lucian R. Chirieac, Ramneet Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, Robert F. Padera, Carlos Garcı́a-Echeverrı́a, Ralph Weissleder, Umar Mahmood, Lewis C. Cantley, Kwok‐Kin Wong
Published 2008Artigo -
12
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC by Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu, Youngchul Song, Dora Dias‐Santagata, Eugene Lifshits, Luca Toschi, Andrew M. Rogers, Tony Mok, Lecia V. Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne
Published 2010Artigo -
13
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models by Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Kenneth E. Hung, Toshi Shioda, Dora Dias‐Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino‐Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman
Published 2012Artigo -
14
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 by Anthony C. Faber, Erin M. Coffee, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J. Edelman, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman
Published 2013Artigo -
15
Activation of PI3K Signaling in Merkel Cell Carcinoma by Valentina Nardi, Youngchul Song, Juan A. Santamaria‐Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, A. John Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias‐Santagata
Published 2012Artigo -
16
BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors by Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, João Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias‐Santagata, Rakesh K. Jain, Jeffrey A. Engelman
Published 2011Artigo -
17
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models by Sen Zhang, Rana Anjum, Rachel M. Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott Wardwell, David F. Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei‐Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish K. Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana I. Narasimhan, Frank Wang, Juan J. Miret, Xiaotian Zhu, Tim Clackson, David C. Dalgarno, William C. Shakespeare, Victor M. Rivera
Published 2016Artigo -
18
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer by Anthony C. Faber, Anna F. Farago, Carlotta Costa, Anahita Dastur, María Gomez‐Caraballo, Rebecca Robbins, Bethany L. Wagner, William M. Rideout, Charles T. Jakubik, Jungoh Ham, Elena J. Edelman, Hiromichi Ebi, Alan T. Yeo, Aaron N. Hata, Youngchul Song, Neha U. Patel, Ryan J. March, Ah Ting Tam, Randy Milano, Jessica L. Boisvert, Mark Hicks, Sarah Elmiligy, Scott Malstrom, Miguel N. Rivera, Hisashi Harada, Brad E. Windle, Sridhar Ramaswamy, Cyril H. Benes, Tyler Jacks, Jeffrey A. Engelman
Published 2015Artigo
Search Tools:
Related Subjects
Cancer research
Biology
Cancer
Medicine
Internal medicine
Genetics
Cell biology
Gene
PI3K/AKT/mTOR pathway
Signal transduction
Colorectal cancer
Lung cancer
Mutant
Receptor
ERBB3
Epidermal growth factor receptor
ErbB
KRAS
Kinase
MAPK/ERK pathway
Oncology
Pharmacology
Protein kinase B
Receptor tyrosine kinase
Apoptosis
Chemistry
Combination therapy
Gefitinib
MEK inhibitor
Antibody